# ARQ 197 in Subjects With Metastatic Solid Tumors

> **NCT00302172** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 78 (estimated)

## Conditions studied

- Cancer
- Tumor

## Interventions

- **DRUG:** ARQ 197

## Key facts

- **NCT ID:** NCT00302172
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2009-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00302172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00302172, "ARQ 197 in Subjects With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00302172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*